23 JULY 2019 INVESTOR OPEN DAY CEO PAUL SWINNEY CFO LIZ DIXON The - - PowerPoint PPT Presentation

23 JULY 2019 INVESTOR OPEN DAY

CEO PAUL SWINNEY CFO LIZ DIXON

2

The World of Infection Prevention

Medical Devices Skin Surfaces Water

The World of Chlorine Dioxide

3

Pro ropri rietary Formu mulation

• n

High C Conc ncent ntration Suitab able For S Special alit ity Applic icat atio ions: s: Medical Devices Surfaces Comm mmod

• dity

Low C Concentr trati tion Suitab able F For Indust strial al A Applicatio ions: s: Paper Bleaching Water Disinfection

How Do We Make Chlorine Dioxide

4

Citric Acid Sodium Chlorite Chlorine Dioxide Sodium Citrate Salt

Multiple User Sites in Hospitals Worldwide

5

Device ce: End Endocavity Pro robe Diagno gnosis: : End Endometriosis Department nt: : Ultras asound Device ce: Nas asendosc scope Diagno gnosis: : Cleft Pa t Palate te Department nt: : Ear ar, Nose se & T Throat Device ce: Lar Laryngoscope Pur urpo pose: e: Intuba bati tion Department nt: : Acci cide dent & & Emer ergen ency

Regulation Drives Demand

6

Semi-Critical Classification High-level Disinfection Invasive Device

Tristel’s Chlorine Dioxide

£20.5m £2.2m

ClO2 Medical Devices ClO2 Other

ClO2 (Core)

£22.7m

Non ClO2 (Non-core)

£3.3m Medical devices Other

7

Sales Growth: Core vs Non-Core

£0 £5,000,000 £10,000,000 £15,000,000 £20,000,000 £25,000,000 £30,000,000 2015-16 2016-17 2017-18 2018-19

8

+ 2 24% 4% + 11% 11%

• 5%

5%

CORE ClO2 Medical Devices ClO2 Other NON-CORE Non ClO2

Intellectual property protection

9

Guidelines (19) Proprietary Formulation Published Papers (29) Patents (6) Families (233) Grants (66) Applications In Progress Manufacturers Compatibility (55) Individual Device Compatibility (1,845)

The Key Dynamics of The Business + International: growing fast (2019: +25%) + Medical devices (ClO2): growing fast (2019: +24%) + Surfaces (ClO2): picking up pace (2019: +11%)

• Growth held back by declining non-core sales (2019: -5%)

10

Total Sales Growth History

£0 £5,000,000 £10,000,000 £15,000,000 £20,000,000 £25,000,000 £30,000,000

11

CAGR 17%

Total Sales Growth History

£0 £5,000,000 £10,000,000 £15,000,000 £20,000,000 £25,000,000 £30,000,000

UK sales International sales

12

International Sales Growth History

£0 £2,000,000 £4,000,000 £6,000,000 £8,000,000 £10,000,000 £12,000,000 £14,000,000 £16,000,000

13

CAGR 53%

International Sales Growth History

£0 £2,000,000 £4,000,000 £6,000,000 £8,000,000 £10,000,000 £12,000,000 £14,000,000 £16,000,000

Distributors Europe Direct Asia Pacific Direct

14

Global Distributors

15

Global Subsidiaries

Active Approvals in process

16

ClO2 Medical Devices

£0 £5,000,000 £10,000,000 £15,000,000 £20,000,000 £25,000,000

17

CAGR 39%

Sales Performance Vs Target 2016-2019

£15,000,000 £17,000,000 £19,000,000 £21,000,000 £23,000,000 £25,000,000 £27,000,000 2015-16 2016-17 2017-18 2018-19 Sales actual

15% 15% 10% 10% 10% 15%

18

Profitability Target 2016-2019 Targeted PBT* margin: 17.5% Actual PBT* margin: 2016-17 20% 2017-18 21% 2018-19 21%

**before share based payments and after expensing USA regulatory costs

19

Profit*

£0 £1,000,000 £2,000,000 £3,000,000 £4,000,000 £5,000,000 £6,000,000 £7,000,000 £8,000,000 2015-16 2016-17 2017-18 2018-19 Adjusted PBT Brokers forecast *before tax and share based payments

20

Cash 2017-2019 Cash generated: £19m Cash utilisation: Investments & acquisitions £9m Capital expenditure £2m Dividends £7m Working capital & tax £3m Net cash reduction: £2m

21

22

A high growth, broadly based business. Three year financial targets beaten. Surplus cash re-invested into sales and profit growth. 2019 Achievements

23

Major Initiatives

United States Julija Shabanova Surfaces Elanor Dixon Point of Care Ultrasound (POCUS) Bart Leemans Women’s Health Danielle Smith 3T Esther Jansen Crystel Rob Lewis

24

United States

Semi mi-crit itic ical devic ices Hig igh- leve vel dis isinfectant DeNovo vo pathway y Usability a and human f n factors study: Pre re-subm bmission

• n review u

ew underway Focus on n Ultr ltrasound Spe pend t to dat ate £1. £1.5m

Thank you Q&A

25